Research map: Occult metastases detection and impact on management in renal cell carcinoma imaged with [89Zr]Zr-girentuximab

Back to the article

Papers in this map

  1. [89Zr]Zr-girentuximab for PET–CT imaging of clear-cell renal cell carcinoma: a prospective, open-label, multicentre, phase 3 trial · Brian M. Shuch · 2024 · 152 citations · Cited by this paper
  2. Real-world evaluation of [177Lu]Lu-PSMA-617 RLT in post-taxane mCRPC: feasibility and safety of individualized treatment in a challenging cohort · 2026 · Related
  3. Phase I study to assess safety, biodistribution and radiation dosimetry for 89Zr-girentuximab in patients with renal cell carcinoma · Robin I. J. Merkx · 2021 · 76 citations · Cited by this paper
  4. Whole-body TSPO-PET reveals stage-dependent disruption of systemic immune organ interactions in glioblastoma · 2026 · Related
  5. Cryoablation of Bone Metastases from Renal Cell Carcinoma for Local Tumor Control · Carly S. Gardner · 2017 · 60 citations · Cited by this paper
  6. Evaluation of treatment efficacy of the 161Tb- and 177Lu-Labeled GRPR antagonists AMTG and RM2 in a mouse model of prostate cancer · 2026 · Related
  7. Metastasis-directed radiotherapy without systemic therapy for oligometastatic clear-cell renal-cell carcinoma: primary efficacy analysis of a single-arm, single-centre, phase 2 trial · Chad Z. Tang · 2025 · 19 citations · Cited by this paper
  8. From image reconstruction to clinical prognosis: A comprehensive analysis of centiloid-based amyloid PET assessment · 2026 · Related
  9. Percutaneous Cryoablation of Recurrent or Oligometastatic Tumors in Thoracoabdominal Soft Tissues: Safety, Effectiveness, and Technical Aspects · Giuseppina Pacella · 2023 · 6 citations · Cited by this paper
  10. [18F]FDG PET during immunotherapy: mind the gap between evidence, imaging guidelines, and oncology practice · 2026 · Related
  11. SNMMI/EANM/ACNM Procedure Standard/Procedure Guideline on the Use of Molecular Imaging for Renal Mass Characterization · Steven P. Rowe · 2025 · 3 citations · Cited by this paper
  12. CSF proteomic pathway alterations and caudate dopamine transporter deficits predict cognitive vulnerability in early Parkinson’s disease · 2026 · Related
  13. Skeletal muscle radiodensity as an automated survival predictor in men with metastatic castration-resistant prostate cancer undergoing PSMA-targeted radioligand therapy · 2026 · Related
  14. In vivo multimodal PET/MRI imaging and plasma biomarkers implicate glymphatic dysfunction linking neuroinflammation to tau pathology in the early Alzheimer’s disease continuum · 2026 · Related
  15. Prospective comparison of [68Ga]Ga-FAPI-04 PET/MRI, [18F]FDG PET/CT, and contrast-enhanced MRI for predicting pathologic complete response after neoadjuvant chemotherapy in breast cancer · 2026 · Related
  16. 68Ga-PSMA PET/CT in biochemically recurrent prostate cancer: association with genomic data · 2026 · Related

Source: OpenAlex (CC0)